Our Opinion

Xilio Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of its medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“The new data demonstrate preclinical proof-of-concept for these molecules with significant anti-tumor effects and minimal peripheral effects in animal models, significantly widening the potential therapeutic index for these therapies vs. currently available treatments.” Read the following article

Company Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Company Website: https://xiliotx.com